CCT6A and cancer: In line with this, we found significantly increased expression of HSPA2 (better prognosis) in TP53 WT cancers (log2 FC = 0,99; p < 0,0001), whereas high expression of HSP90AA1, CCT1, CCT2 and CCT6A (poor prognosis) coincided with TP53 mutations (HSP90AA1 log2 FC = 0,18; p < 0,0001; CCT1 log2 FC = 0,99; p < 0,0001; CCT2 log2 FC = 0,15; p = 0,0047; CCT6A log2 FC = 0,65; p < 0,0001, respectively) (Fig. 3).